(DDD) 3D Systems - Overview
Stock: Printers, Materials, Software, Services
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 96.9% |
| Relative Tail Risk | -21.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.33 |
| Alpha | -78.84 |
| Character TTM | |
|---|---|
| Beta | 1.849 |
| Beta Downside | 1.298 |
| Drawdowns 3y | |
|---|---|
| Max DD | 88.25% |
| CAGR/Max DD | -0.47 |
Description: DDD 3D Systems December 31, 2025
3D Systems (NYSE:DDD) operates globally across North America, Europe, APAC, the Middle East, Africa and Oceania, delivering 3D printing and digital manufacturing solutions through two primary segments: Healthcare Solutions and Industrial Solutions.
The company’s technology suite spans stereolithography (SLA), selective laser sintering (SLS), direct metal laser sintering (DMLS), MultiJet, ColorJet, polymer extrusion, and bioprinting platforms, supported by a broad material portfolio that includes plastics, nylons, metals, composites, elastomers, waxes, dental polymers, and biocompatible resins. Complementary offerings encompass design software (3D Sprint, 3DXpert), the Oqton manufacturing operating system, scanners, haptic devices, and a range of services from maintenance and training to cloud-based software subscriptions.
In FY 2023, 3D Systems generated roughly $1.5 billion in revenue, with the Healthcare Solutions segment contributing about 38% and showing a year-over-year growth rate of 12% driven by rising demand for patient-specific implants and surgical guides. The additive manufacturing market is projected to expand at a CAGR of ~14% through 2029, fueled by increasing adoption in aerospace, automotive lightweighting, and on-demand production models-trends that directly benefit DDD’s diversified customer base. For a deeper, data-driven view of how these macro-drivers translate into valuation signals, consider exploring the company’s profile on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: 15.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.17 > 0.02 and ΔFCF/TA -7.44 > 1.0 |
| NWC/Revenue: 58.44% < 20% (prev 72.33%; Δ -13.89% < -1%) |
| CFO/TA -0.15 > 3% & CFO -80.9m > Net Income 15.7m |
| Net Debt (97.7m) to EBITDA (57.5m): 1.70 < 3 |
| Current Ratio: 2.73 > 1.5 & < 3 |
| Outstanding Shares: last quarter (125.3m) vs 12m ago -5.26% < -2% |
| Gross Margin: 33.76% > 18% (prev 0.40%; Δ 3336 % > 0.5%) |
| Asset Turnover: 64.58% > 50% (prev 67.44%; Δ -2.86% > 0%) |
| Interest Coverage Ratio: 9.61 > 6 (EBITDA TTM 57.5m / Interest Expense TTM 3.82m) |
Altman Z'' -8.91
| A: 0.41 (Total Current Assets 361.2m - Total Current Liabilities 132.3m) / Total Assets 554.5m |
| B: -2.37 (Retained Earnings -1.31b / Total Assets 554.5m) |
| C: 0.06 (EBIT TTM 36.7m / Avg Total Assets 606.4m) |
| D: -4.10 (Book Value of Equity -1.36b / Total Liabilities 331.3m) |
| Altman-Z'' Score: -8.91 = D |
Beneish M -2.65
| DSRI: 1.01 (Receivables 88.1m/99.2m, Revenue 391.7m/443.9m) |
| GMI: 1.18 (GM 33.76% / 39.98%) |
| AQI: 1.18 (AQ_t 0.15 / AQ_t-1 0.13) |
| SGI: 0.88 (Revenue 391.7m / 443.9m) |
| TATA: 0.17 (NI 15.7m - CFO -80.9m) / TA 554.5m) |
| Beneish M-Score: -2.65 (Cap -4..+1) = A |
What is the price of DDD shares?
Over the past week, the price has changed by -1.79%, over one month by -0.90%, over three months by -2.22% and over the past year by -52.99%.
Is DDD a buy, sell or hold?
- StrongBuy: 1
- Buy: 0
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the DDD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 3.6 | 65% |
| Analysts Target Price | 3.6 | 65% |
| ValueRay Target Price | 1.5 | -31.8% |
DDD Fundamental Data Overview February 03, 2026
P/S = 0.8354
P/B = 1.526
P/EG = 2.98
Revenue TTM = 391.7m USD
EBIT TTM = 36.7m USD
EBITDA TTM = 57.5m USD
Long Term Debt = 122.6m USD (from longTermDebt, last quarter)
Short Term Debt = 13.4m USD (from shortTermDebt, last quarter)
Debt = 193.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 97.7m USD (from netDebt column, last quarter)
Enterprise Value = 424.8m USD (327.2m + Debt 193.2m - CCE 95.5m)
Interest Coverage Ratio = 9.61 (Ebit TTM 36.7m / Interest Expense TTM 3.82m)
EV/FCF = -4.51x (Enterprise Value 424.8m / FCF TTM -94.2m)
FCF Yield = -22.18% (FCF TTM -94.2m / Enterprise Value 424.8m)
FCF Margin = -24.06% (FCF TTM -94.2m / Revenue TTM 391.7m)
Net Margin = 4.01% (Net Income TTM 15.7m / Revenue TTM 391.7m)
Gross Margin = 33.76% ((Revenue TTM 391.7m - Cost of Revenue TTM 259.4m) / Revenue TTM)
Gross Margin QoQ = 31.73% (prev 38.12%)
Tobins Q-Ratio = 0.77 (Enterprise Value 424.8m / Total Assets 554.5m)
Interest Expense / Debt = 1.00% (Interest Expense 1.92m / Debt 193.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = 29.0m (EBIT 36.7m * (1 - 21.00%))
Current Ratio = 2.73 (Total Current Assets 361.2m / Total Current Liabilities 132.3m)
Debt / Equity = 0.87 (Debt 193.2m / totalStockholderEquity, last quarter 221.1m)
Debt / EBITDA = 1.70 (Net Debt 97.7m / EBITDA 57.5m)
Debt / FCF = -1.04 (negative FCF - burning cash) (Net Debt 97.7m / FCF TTM -94.2m)
Total Stockholder Equity = 196.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 2.59% (Net Income 15.7m / Total Assets 554.5m)
RoE = 8.00% (Net Income TTM 15.7m / Total Stockholder Equity 196.0m)
RoCE = 11.53% (EBIT 36.7m / Capital Employed (Equity 196.0m + L.T.Debt 122.6m))
RoIC = 7.99% (NOPAT 29.0m / Invested Capital 363.4m)
WACC = 8.30% (E(327.2m)/V(520.4m) * Re(12.73%) + D(193.2m)/V(520.4m) * Rd(1.00%) * (1-Tc(0.21)))
Discount Rate = 12.73% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.84%
Fair Price DCF = unknown (Cash Flow -94.2m)
EPS Correlation: -27.89 | EPS CAGR: 6.44% | SUE: 1.19 | # QB: 1
Revenue Correlation: -94.44 | Revenue CAGR: -12.55% | SUE: -0.51 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.10 | Chg30d=-0.037 | Revisions Net=-2 | Analysts=3
EPS next Year (2026-12-31): EPS=-0.33 | Chg30d=-0.163 | Revisions Net=-3 | Growth EPS=+28.2% | Growth Revenue=+1.3%